It is recognized that the primary goals of disease-modifying treatment in ALS are to abrogate the accrual of disability and prolong survival, so that measurement of plasma NFL might support, but not currently replace, established clinical outcome measures in phase III trials. The gene discussed is NEFL; the disease is amyotrophic lateral sclerosis.